1. Home
  2. AGPU vs ACRV Comparison

AGPU vs ACRV Comparison

Compare AGPU & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axe Compute Inc. Common Stock

AGPU

Axe Compute Inc. Common Stock

HOLD

Current Price

$10.68

Market Cap

83.5M

Sector

N/A

ML Signal

HOLD

Logo Acrivon Therapeutics Inc.

ACRV

Acrivon Therapeutics Inc.

HOLD

Current Price

$2.21

Market Cap

74.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGPU
ACRV
Founded
2002
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.5M
74.0M
IPO Year
2008
2022

Fundamental Metrics

Financial Performance
Metric
AGPU
ACRV
Price
$10.68
$2.21
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$11.67
AVG Volume (30 Days)
561.9K
382.5K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
15.13
EPS
N/A
N/A
Revenue
$125,284.00
N/A
Revenue This Year
$12,476.23
N/A
Revenue Next Year
$55.17
$568.17
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.03
$1.27
52 Week High
$10.92
$3.56

Technical Indicators

Market Signals
Indicator
AGPU
ACRV
Relative Strength Index (RSI) 64.17 70.10
Support Level $6.26 $2.14
Resistance Level $10.86 $2.48
Average True Range (ATR) 1.02 0.12
MACD 0.24 0.07
Stochastic Oscillator 88.39 84.58

Price Performance

Historical Comparison
AGPU
ACRV

About AGPU Axe Compute Inc. Common Stock

Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, the company aims to provide access to bare-metal GPUs at scale for both emerging and established organizations.

About ACRV Acrivon Therapeutics Inc.

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.

Share on Social Networks: